ORCHPHARMA Q1 FY27 earnings call.

Guidance to track

• Target 80-100% utilization by end of first year of operation, with 80% for captive consumption and 20% for third-party sales once customer approvals are obtained from the new Jammu site.
• Facility target ready by December 2026, with first commercial batch expected in January-March 2027, subject to DCGI trial waiver approval which takes 6-9 months.
• First commercial batch targeting March 2027 from Jammu facility, representing 20x scale-up from existing pilot plant, with another 800x scale-up planned for full production.
• Plan to file with WHO Geneva for Product Quality certification to enable simplified registrations across multiple countries, taking approximately two years for approval.

Risks flagged

• Chinese manufacturers controlling 3-4 players in 7 ACA globally could potentially engage in aggressive pricing when Indian capacity enters, though management cited stable $60 weighted average pricing for 10+ years and belief that private Chinese enterprises now seek profitability.
• Cefixime is under maximum margin stress particularly in rest-of-world markets where volumes are highest and competition fiercest. Management acknowledged this product is derived from PNG where Orchid lacks backward integration, creating ongoing vulnerability.
• Se Pro DCGI trial waiver outcome uncertain despite Orchid's precedent with Focablat; commercial launch timeline depends on regulatory committee decision post-application. WHO PQ process takes ~2 years.
• Management acknowledged integration benefits from merger will emerge progressively, with initial visible benefits only from next financial year (FY28), creating near-term margin headwind.

Key quotes

• Financial year 26 was a difficult year for Cephalosporin business. It was among the most challenging environments our surplus in franchise has faced in the last 15 to 20 years. In a number of important products and markets, both volumes and pricing were affected with declines of 15 to 20% depending on the product.
• While we have seen some improvement in sales over last year, we feel the industry is still facing overcapacities leading to cutthroat competition. Our focus remains on growing volumes with discipline, improving product mix, maintaining strict control over operating costs and progressively strengthening the underlying profitability of the combined platform.
• I have changed my thinking about the Chinese. If I find the Chinese selling something cheaper, I would want to believe that their technology is better and I should look at my technology. That's my belief these days.